We are live on ! Find out more
ProShare Advisors

ProShare Advisors Portfolio holdings

AUM $67.5B
1-Year Est. Return 28.09%
This Fund
S&P 500
This Quarter Est. Return
+8.87%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$34.2B
AUM Growth
+$2.41B
Cap. Flow
-$59.6M
Cap. Flow %
-0.17%
Top 10 Hldgs %
26.19%
Holding
2,465
New
206
Increased
1,202
Reduced
956
Closed
98

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$31.6M
2
PETS icon
PetMed Express
PETS
+$29.7M
3
ALB icon
Albemarle
ALB
+$27.7M
4
WMT icon
Walmart Inc
WMT
+$27.2M
5
NEE icon
NextEra Energy
NEE
+$27M

Sector Composition

Rank Sector Weight
1 Technology 25.69%
2 Consumer Discretionary 14.5%
3 Communication Services 10.43%
4 Healthcare 10.27%
5 Financials 9.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SB icon
2351
Safe Bulkers
SB
$734M
$57K ﹤0.01%
14,244
+378
+3% +$1.32K
SLDB icon
2352
Solid Biosciences
SLDB
$843M
$57K ﹤0.01%
+1,031
New +$68.1K
HOFV
2353
DELISTED
Hall of Fame Resort & Entertainment Co
HOFV
$56K ﹤0.01%
+648
New +$56.1K
ONCT
2354
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$55K ﹤0.01%
+574
New +$68.1K
ORTX
2355
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$53K ﹤0.01%
+1,201
New +$66.9K
STR
2356
DELISTED
Sitio Royalties
STR
$52K ﹤0.01%
2,582
+31
+1% +$595
SEEL
2357
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$52K ﹤0.01%
+5
New +$82.2K
VATE icon
2358
INNOVATE Corp
VATE
$122M
$49K ﹤0.01%
1,229
-93
-7% -$3.76K
XERS icon
2359
Xeris Biopharma Holdings
XERS
$1.5B
$49K ﹤0.01%
11,925
-8,539
-42% -$32.6K
CHMA
2360
DELISTED
Chiasma, Inc. Common Stock
CHMA
$49K ﹤0.01%
10,402
-10,983
-51% -$41.4K
OVID icon
2361
Ovid Therapeutics
OVID
$440M
$48K ﹤0.01%
12,183
-9,306
-43% -$36.7K
FRBK
2362
DELISTED
Republic First Bancorp Inc
FRBK
$46K ﹤0.01%
11,600
-546
-4% -$2.19K
AVTX icon
2363
Avalo Therapeutics
AVTX
$972M
$45K ﹤0.01%
5
+1
+25% +$8.38K
MBII
2364
DELISTED
Marrone Bio Innovations, Inc.
MBII
$43K ﹤0.01%
25,991
+7,461
+40% +$12.5K
RVLP
2365
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$34K ﹤0.01%
11,269
-784
-7% -$2.4K
FLNT
2366
Fluent
FLNT
$111M
$33K ﹤0.01%
1,875
+12
+0.6% +$237
CALA
2367
DELISTED
Calithera Biosciences, Inc
CALA
$28K ﹤0.01%
665
-705
-51% -$31K
ABEO icon
2368
Abeona Therapeutics
ABEO
$373M
-645
Closed -$30K
ADMA icon
2369
ADMA Biologics
ADMA
$2.02B
-17,612
Closed -$31K
AGX icon
2370
Argan
AGX
$8.45B
-3,939
Closed -$210K
ARTNA icon
2371
Artesian Resources
ARTNA
$352M
-307,092
Closed -$12.1M
ASMB icon
2372
Assembly Biosciences
ASMB
$504M
-1,123
Closed -$62K
BAH icon
2373
Booz Allen Hamilton
BAH
$7.87B
-25,715
Closed -$2.07M
BEPC icon
2374
Brookfield Renewable
BEPC
$6.2B
-34,391
Closed -$1.61M
BHB icon
2375
Bar Harbor Bankshares
BHB
$637M
-382,409
Closed -$11.3M

Similar funds

ProShare Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, ProShare Advisors held 2,465 positions worth $34.2B, up 7.6% from $31.8B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

ProShare Advisors's Q2 2021 filing shows 206 new, 1,202 increased, 956 reduced and 98 closed positions. Its largest new stake was Trinity Industries: 371,743 shares worth $10M. The largest sale was Amazon, an estimated $155M.

By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • ProShare Advisors's largest Q2 2021 buy was Trinity Industries: 371,743 shares worth $10M.
  • ProShare Advisors added most to Johnson & Johnson in Q2 2021, an estimated $31.6M increase.
  • ProShare Advisors's biggest Q2 2021 reduction was Amazon, cutting an estimated $155M.
  • ProShare Advisors fully exited Just Eat Takeaway.com N.V. American Depositary Shares in Q2 2021, selling an estimated $60.1M.
  • ProShare Advisors's ten largest holdings make up 26% of its $34.2B portfolio in Q2 2021.
  • ProShare Advisors opened 206 new positions and closed 98 in Q2 2021.
  • ProShare Advisors's portfolio value rose 7.6% quarter-over-quarter to $34.2B.

Based on ProShare Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.